A study by researchers at the Hebrew University of Jerusalem has found that non-psychoactive cannabis compounds, CBD and CBG, can improve blood sugar control, reduce liver fat, and lower harmful blood lipids in obese mice with metabolic dysfunction-associated steatotic liver disease (MASLD). The study was published in the British Journal of Pharmacology. The compounds were given through daily abdominal injections, not the tinctures and capsules. Despite these limitations, the researchers believe this early study could lead to significant improvements in the treatment of MASLD, which affects one-third of the adult population.